Survivor: Novo Nordisk Sets Levemir Apart Amid Synthetic Insulin Scare
Executive Summary
There will be winners and losers for the makers of type 2 diabetes drugs as doctors and patients absorb news of a potentially higher cancer risk for Sanofi-Aventis' long-acting insulin Lantus. Not surprisingly, Novo Nordisk is working hard to come out on top in any shakeout and held a recent presentation to make its case to investors
You may also be interested in...
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.